In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemline Therapeutics Inc.

www.stemline.com

Latest From Stemline Therapeutics Inc.

Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise

Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011. 

Medicare Reimbursement

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Novartis’s Zolgensma Loses EU Accelerated Assessment

Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.

Europe Drug Review

EU Accelerated Assessment – Hard To Get, Hard To Keep

It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.

Review Pathway Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Stemline Therapeutics Inc.
  • Senior Management
  • Ivan Bergstein, MD, Pres. & CEO
    Kenneth Hoberman, COO
    David Gionco, VP, Fin. & Chief Accounting Officer
  • Contact Info
  • Stemline Therapeutics Inc.
    Phone: (646) 502-2310
    750 Lexington Ave.
    11th Fl.
    New York, NY 10022
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register